Találati lista | Tudóstér

001-es BibID:	BIBFORM001953
Első szerző:	Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:	Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus : results from a single center / Tarr T., Gyorfy B., Szekanecz E., Bhattoa H. P., Zeher M., Szegedi G., Kiss E.
Dátum:	2007
Megjegyzések:	As a result of increasing life expectancy of lupus patients, malignant disorders have become major determinants of morbidity and mortality. The objectives of this study were to analyze cancer-associated morbidity and mortality, the type of malignancies in Hungarian lupus patients, and to analyze association with immune-suppressive therapy, disease duration, and age of the patients. Data from 860 systemic lupus erythematosus (SLE) patients were retrospectively analyzed in a study period between 1970 and 2004. Results were compared to data from age- and sex-matched population obtained from the Health for All database, and also to literature data. A total of 37 patients presented with cancer, reflecting 4.3% cancer-associated morbidity. Patients were 47 (20-73) years old at the onset of malignancy, which appeared 13 (1-45) years later than SLE. Cancer prevalence was the highest in the first 5-10 years of lupus. Breast cancer was the most common malignancy (n = 11) followed by gastrointestinal tumors (n = 9), cervix cancer and hematologic malignancies (n = 5 for both), bronchial cancer (n = 4), bladder, skin, and ovarian cancer (n = 1 for each). Standardized incidence ratio was the highest for non-Hodgkin lymphoma (standardized incidence ratio [SIR] 3.5, 95% CI 0.4-12.5) and cervix cancer (SIR 1.7, 95% CI 0.6-4.1). Although 76% of patients with cancer received immune-suppressive therapy besides corticosteroids, no direct correlation could be confirmed between therapy and malignancy. Out of the 164 patients that expired during the study period, 18 were cancer-related. As such the cancer-associated mortality was 11% (18/164). This peaked during the last 4 years of the study period (8/24, 33%). Lupus patients are at high risk for particular types of malignant disorders, highlighting the importance of screening measures and focused patient examination.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban lupus cancer malignancy lymphoma azathioprine chloroquine corticosteroid cyclophosphamide cyclosporin A immunosuppressive agent methotrexate adult aged bladder cancer breast cancer bronchus cancer conference paper controlled study data analysis data base disease association disease duration female gastrointestinal tumor hematologic malignancy human Hungary immunosuppressive treatment incidence male morbidity mortality nonhodgkin lymphoma ovary cancer prevalence retrospective study skin cancer standardization systemic lupus erythematosus uterine cervix cancer Adult Age of Onset Aged Humans Hungary Immunosuppressive Agents Lupus Erythematosus, Systemic Middle Aged Neoplasms Retrospective Studies egyetemen (Magyarországon) készült közlemény
Megjelenés:	Annals of the New York Academy of Sciences 1108 (2007), p. 76-82. -
További szerzők:	Gyorfy Balázs Szekanecz Éva (1968-) (onkológus szakorvos) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI Szerző által megadott URL
Borító:
Saját polcon: